Menlo Park, California-based Refuge Biotechnologies Inc, a developer of intelligent cell therapies to combat cancer, has secured $25 million in Series B funding. The lead investors were 3SBio and Sequoia China. Also, participating in the round were Danhua Capital, Sangel Capital, Ocean Pine Healthcare Fund, 3E Bioventures, WuXi Healthcare Ventures and ShangBay Capital. In addition to the funding, Dr. Zhenping Zhu of 3SBio and Dr. Trency Gu of Sequoia China, have joined the Refuge board of directors.
Source: Press Release